GLP-1 medications have transformed obesity treatment but remain largely inaccessible through public healthcare. Brazil's SUS approved semaglutide yet still doesn't offer it. Here's why.
The global obesity epidemic has put enormous pressure on governments to find solutions. According to the World Health Organization, worldwide obesity has nearly tripled since 1975, with over 650 million adults now classified as obese. GLP-1 receptor agonists like semaglutide represent a breakthrough in obesity treatment, yet getting these medications to patients through public health systems remains an enormous challenge. If you want to follow developments on this topic, OzemNews covers these issues regularly.
The Growing Demand for GLP-1 Medications in Public Healthcare
Countries around the world face mounting pressure to address obesity as a public health crisis. Several have attempted to include GLP-1 drugs in public coverage programs, but regulatory approval does not automatically translate into population access. The path from clinical evidence to public system inclusion involves multiple layers of evaluation, funding decisions, and infrastructure planning that can take years to navigate.
The Brazilian SUS Context — Approved but Not Accessible
Brazil offers an instructive case study. Semaglutide received approval from ANVISA, the Brazilian health regulatory agency, yet it remains absent from the public system essential medication list. The gap exists because the Brazilian health technology assessment body, CONITEC, evaluates medications for SUS inclusion by assessing clinical efficacy, cost-effectiveness, and budget impact. This process often takes years to complete.
CONITEC did recommend semaglutide for type 2 diabetes in 2020, but even this recommendation has not resulted in routine availability at public health facilities. The reality is that approval and actual access exist in different worlds. When expensive medications enter the picture, budget constraints become the deciding factor.
The Price Problem — Why GLP-1 Drugs Stay Out of Reach
Cost remains the central barrier. Monthly GLP-1 treatment can run hundreds to over a thousand dollars per patient depending on the medication and dosage. By comparison, older diabetes medications like metformin cost mere pennies per day. Manufacturing costs for biological drugs do contribute to higher prices, but patent protection and market exclusivity keep generic alternatives unavailable for years after original approval. Novo Nordisk holds key patent protections that have extended market exclusivity for semaglutide.
For public health systems operating under fixed budgets, covering GLP-1 medications for millions of potential patients means difficult tradeoffs. The economics reveal a stark reality: obesity treatment through these medications costs significantly more per patient than most existing chronic disease programs, making universal coverage challenging to justify against competing priorities.
Infrastructure and Clinical Readiness Challenges
Even if prices dropped tomorrow, healthcare systems would still face implementation hurdles. GLP-1 medications require ongoing medical supervision, regular follow-up appointments, and continuous patient monitoring. These demands strain specialist availability, particularly endocrinology services that already face long wait times in public systems. Primary care providers often lack the training needed to prescribe and manage these medications appropriately.
Healthcare systems accustomed to one-time treatments or simple medication distributions struggle with the continuous care model that GLP-1 therapy demands. Supply chain limitations also emerge when sudden demand increases, as demonstrated by shortages that occurred globally when Wegovy gained popularity.
Who Gets Left Behind — Equity and Eligibility Concerns
When public programs do include GLP-1 coverage, eligibility criteria often narrow the population significantly. Most systems prioritize diabetes management where evidence is strongest and cost-effectiveness clearer, leaving obesity-only patients without coverage. Age restrictions and comorbidity requirements create additional barriers that exclude many who could benefit from treatment.
Geographic disparities compound these issues. Urban centers typically have better medication availability than rural areas, creating a patchwork where access depends heavily on location. The risk of a two-tier system within public coverage grows when implementation varies so dramatically across regions.
What Would Actually Close the Gap — Realistic Paths Forward
Several approaches could improve access over time. Generic competition and biosimilar approvals, likely emerging in the late 2020s or early 2030s, could reduce prices substantially once available. Risk-sharing agreements where governments pay based on patient outcomes rather than upfront medication costs represent another avenue worth exploring.
Integrating lifestyle support alongside medication may improve outcomes and strengthen the case for public investment. Clinical guidelines from bodies like NICE in the UK demonstrate how systematic approaches shape coverage decisions, providing models other health systems can adapt to their contexts.
What the Evidence Shows About Long-Term Public Viability
Clinical trial data reveals that patients often regain weight after stopping GLP-1 medications, raising questions about indefinite treatment use and its long-term cost implications for public systems. The UK NHS has gained some practical experience through limited pilot programs, though these initiatives remain modest in scope.
The honest conversation stakeholders need to have involves recognizing that while GLP-1 medications offer genuine clinical benefits, integrating them into taxpayer-funded systems requires realistic assessment of ongoing costs, implementation timelines, and what health systems can actually sustain. For those tracking how different countries navigate these challenges, OzemNews continues following these developments closely.
FAQ
Why aren't GLP-1 medications available through Brazil's public system?
Cost remains the fundamental barrier. Monthly GLP-1 treatment costs hundreds to over a thousand dollars per patient, making universal coverage economically challenging for a public system serving millions.
Has semaglutide received any approval in Brazil?
ANVISA, Brazil's health regulatory agency, has approved semaglutide. CONITEC recommended it for type 2 diabetes in 2020, but it has not been incorporated into the essential medicines list for routine availability.
Do any countries offer GLP-1 coverage through public healthcare?
The UK NHS has begun offering semaglutide for weight management in specific cases through limited programs, though widespread public coverage remains rare globally.
When might generic GLP-1 options become available?
Generic alternatives are likely still years away. Patent protections and the complexity of biological drugs extend the timeline for affordable alternatives to reach markets.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
